BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 25409711)

  • 1. High mobility group A1 protein expression reduces the sensitivity of colon and thyroid cancer cells to antineoplastic drugs.
    D'Angelo D; Mussnich P; Rosa R; Bianco R; Tortora G; Fusco A
    BMC Cancer; 2014 Nov; 14():851. PubMed ID: 25409711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lentivirus-mediated RNA interference of HMGA1 promotes chemosensitivity to gemcitabine in pancreatic adenocarcinoma.
    Liau SS; Ashley SW; Whang EE
    J Gastrointest Surg; 2006 Nov; 10(9):1254-62; discussion 1263. PubMed ID: 17114012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Silencing of high mobility group A1 enhances gemcitabine chemosensitivity of lung adenocarcinoma cells.
    Cao YD; Huang PL; Sun XC; Ma J; Jin ZL; Cheng HY; Xu RZ; Li F; Qin SK; Deng YX; Ge XL
    Chin Med J (Engl); 2011 Apr; 124(7):1061-8. PubMed ID: 21542969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overexpression of HMGA1 promotes anoikis resistance and constitutive Akt activation in pancreatic adenocarcinoma cells.
    Liau SS; Jazag A; Ito K; Whang EE
    Br J Cancer; 2007 Mar; 96(6):993-1000. PubMed ID: 17342093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased TGF-α as a mechanism of acquired resistance to the anti-EGFR inhibitor cetuximab through EGFR-MET interaction and activation of MET signaling in colon cancer cells.
    Troiani T; Martinelli E; Napolitano S; Vitagliano D; Ciuffreda LP; Costantino S; Morgillo F; Capasso A; Sforza V; Nappi A; De Palma R; D'Aiuto E; Berrino L; Bianco R; Ciardiello F
    Clin Cancer Res; 2013 Dec; 19(24):6751-65. PubMed ID: 24122793
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Critical role of HMGA proteins in cancer cell chemoresistance.
    D'Angelo D; Mussnich P; Arra C; Battista S; Fusco A
    J Mol Med (Berl); 2017 Apr; 95(4):353-360. PubMed ID: 28293697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HMGA proteins promote ATM expression and enhance cancer cell resistance to genotoxic agents.
    Palmieri D; Valentino T; D'Angelo D; De Martino I; Postiglione I; Pacelli R; Croce CM; Fedele M; Fusco A
    Oncogene; 2011 Jul; 30(27):3024-35. PubMed ID: 21339738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TLR9 agonist acts by different mechanisms synergizing with bevacizumab in sensitive and cetuximab-resistant colon cancer xenografts.
    Damiano V; Caputo R; Garofalo S; Bianco R; Rosa R; Merola G; Gelardi T; Racioppi L; Fontanini G; De Placido S; Kandimalla ER; Agrawal S; Ciardiello F; Tortora G
    Proc Natl Acad Sci U S A; 2007 Jul; 104(30):12468-73. PubMed ID: 17636117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HMGA1 protein expression sensitizes cells to cisplatin-induced cell death.
    Baldassarre G; Belletti B; Battista S; Nicoloso MS; Pentimalli F; Fedele M; Croce CM; Fusco A
    Oncogene; 2005 Oct; 24(45):6809-19. PubMed ID: 16007157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel toll-like receptor 9 agonist induces epidermal growth factor receptor (EGFR) inhibition and synergistic antitumor activity with EGFR inhibitors.
    Damiano V; Caputo R; Bianco R; D'Armiento FP; Leonardi A; De Placido S; Bianco AR; Agrawal S; Ciardiello F; Tortora G
    Clin Cancer Res; 2006 Jan; 12(2):577-83. PubMed ID: 16428503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MicroRNA let‑7d‑5p rescues ovarian cancer cell apoptosis and restores chemosensitivity by regulating the p53 signaling pathway via HMGA1.
    Chen YN; Ren CC; Yang L; Nai MM; Xu YM; Zhang F; Liu Y
    Int J Oncol; 2019 May; 54(5):1771-1784. PubMed ID: 30816441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TGF-β1 induces HMGA1 expression in human breast cancer cells: implications of the involvement of HMGA1 in TGF-β signaling.
    Zu X; Zhong J; Tan J; Tan L; Yang D; Zhang Q; Ding W; Liu W; Wen G; Liu J; Cao R; Jiang Y
    Int J Mol Med; 2015 Mar; 35(3):693-701. PubMed ID: 25572132
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HMGA1 pseudogenes as candidate proto-oncogenic competitive endogenous RNAs.
    Esposito F; De Martino M; Petti MG; Forzati F; Tornincasa M; Federico A; Arra C; Pierantoni GM; Fusco A
    Oncotarget; 2014 Sep; 5(18):8341-54. PubMed ID: 25268743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impairment of the High Mobility Group A (HMGA) protein function contributes to the anticancer activity of trabectedin.
    D'Angelo D; Borbone E; Palmieri D; Uboldi S; Esposito F; Frapolli R; Pacelli R; D'Incalci M; Fusco A
    Eur J Cancer; 2013 Mar; 49(5):1142-51. PubMed ID: 23149213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular aspects on adriamycin interaction with hmga1 regulatory region and its inhibitory effect on HMGA1 expression in human cervical cancer.
    Akhter MZ; Luthra K; Rajeswari MR
    J Biomol Struct Dyn; 2016; 34(4):877-91. PubMed ID: 26084422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effects of small interfering RNA specific to stably transfected HMGA1 gene on biological characters of ovarian carcinoma cells].
    Liu YL; Zheng JH
    Zhonghua Fu Chan Ke Za Zhi; 2010 Jan; 45(1):51-5. PubMed ID: 20367927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HMGA1 induces intestinal polyposis in transgenic mice and drives tumor progression and stem cell properties in colon cancer cells.
    Belton A; Gabrovsky A; Bae YK; Reeves R; Iacobuzio-Donahue C; Huso DL; Resar LM
    PLoS One; 2012; 7(1):e30034. PubMed ID: 22276142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bcl-2 overexpression in thyroid carcinoma cells increases sensitivity to Bcl-2 homology 3 domain inhibition.
    Mitsiades CS; Hayden P; Kotoula V; McMillin DW; McMullan C; Negri J; Delmore JE; Poulaki V; Mitsiades N
    J Clin Endocrinol Metab; 2007 Dec; 92(12):4845-52. PubMed ID: 17848408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidrug mediated re-expression of miRNA targeting the HMGA transcripts in pituitary cells.
    Kitchen MO; Yacqub-Usman K; Emes RD; Richardson A; Clayton RN; Farrell WE
    Pituitary; 2015 Oct; 18(5):674-84. PubMed ID: 25557289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Altered expression of c-IAP1, survivin, and Smac contributes to chemotherapy resistance in thyroid cancer cells.
    Tirrò E; Consoli ML; Massimino M; Manzella L; Frasca F; Sciacca L; Vicari L; Stassi G; Messina L; Messina A; Vigneri P
    Cancer Res; 2006 Apr; 66(8):4263-72. PubMed ID: 16618750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.